Clinical Trials Logo

Encephalomyelitis, Equine clinical trials

View clinical trials related to Encephalomyelitis, Equine.

Filter by:

NCT ID: NCT06002503 Active, not recruiting - Vaccine Reaction Clinical Trials

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Start date: October 16, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and reactogenicity of a VEE DNA Vaccine candidate delivered by either intramuscular or intradermal jet injection. The main question it aims to answer is: • Is the VEE DNA Vaccine candidate safe Participants will: - Receive the VEE DNA Vaccine candidate by either intramuscular or intradermal jet injection - Provide blood and urine samples - Complete ECGs - Complete physical exams - Complete diaries

NCT ID: NCT04131595 Completed - Equine Encephalitis Clinical Trials

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Start date: October 7, 2019
Phase: Phase 1
Study type: Interventional

To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.

NCT ID: NCT03879603 Completed - Clinical trials for Eastern Equine Encephalitis

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

Start date: April 2, 2019
Phase: Phase 1
Study type: Interventional

Western Equine Encephalitis Virus (WEEV), Eastern Equine Encephalitis Virus (EEEV), and Venezuelan Equine Encephalitis Virus (VEEV) are transmitted to humans by infected mosquitoes and can cause encephalitis (swelling of the brain) and other neurological manifestations, including fever, chills, discomfort, feeling sick, muscle pain and then headache, vomiting, restlessness, irritability, seizures, coma, and death. Vaccines teach the body to prevent or fight an infection. When the body learns to fight an infection, this is called an immune response. Researchers developed a vaccine against Western, Eastern and Venezuelan equine encephalitis viruses to help the body make an immune response. There are no live or killed viruses in the vaccine, so you cannot get infected with any of these 3 viruses from getting the vaccine. The experimental trivalent encephalitis vaccine, VRC-WEVVLP073-00-VP, is composed of Western equine encephalitis (WEE), Eastern equine encephalitis (EEE), and Venezuelan equine encephalitis (VEE) virus-like particles (VLP). The purpose of this study is to test three doses (6 mcg, 30 mcg, and 60 mcg) of this experimental vaccine against Western, Eastern and Venezuelan equine encephalitis viruses.

NCT ID: NCT03776994 Active, not recruiting - Clinical trials for Nervous System Diseases

Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine

VEEV
Start date: July 17, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and immunogenicity of non-adjuvanted and adjuvanted monovalent VEE VLP Vaccine in healthy adults (ages 18-50 years) when administered via intramuscular (IM) injection at escalating doses of 2 μg, 10 μg, and 20 μg as a 2-dose primary series (Day 0, Day 28) with a Day 140 booster dose. The secondary objective of the study is to evaluate immunogenicity of the vaccine at the aforementioned time points

NCT ID: NCT03531242 Not yet recruiting - Clinical trials for Venezuelan Equine Encephalomyelitis

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

VEE
Start date: June 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.

NCT ID: NCT03051386 Active, not recruiting - Clinical trials for Venezuelan Equine Encephalomyelitis Virus Disease

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults

VEE
Start date: May 30, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, Live, Attenuated, dried TC-83, NDBR 102, Lot 4, Run 3, and collect data on the incidence of occupational VEE virus infection in vaccinated personnel.

NCT ID: NCT02654509 Completed - Clinical trials for Eastern Equine Encephalitis

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

Start date: June 3, 2008
Phase: Phase 2
Study type: Interventional

This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.

NCT ID: NCT02466750 Recruiting - Clinical trials for Western Equine Encephalitis

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

Start date: December 15, 2015
Phase: Phase 2
Study type: Interventional

This study is being conducted to collect safety and immunogenicity data for the WEE vaccine, TSI-GSD 210. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently).

NCT ID: NCT01984983 Completed - Clinical trials for Venezuelan Equine Encephalitis Virus Infection

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Start date: December 2013
Phase: Phase 1
Study type: Interventional

The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation . The study will enroll 40 healthy adult volunteers ages 18-49 and will comprise evaluation of intradermal or intramuscular administration by electroporation. Administration of the vaccine candidate will be at two DNA dose levels (0.5 mg/ml and 2.0 mg/ml) for each route of administration. Electroporation will be administered using the TriGrid Delivery System devices for intramuscular and intradermal delivery. An additional group of subjects will serve as a placebo control, receiving injections of saline with electroporation. The overall goal of this study will be to determine if further human clinical studies of the vaccine candidate are warranted and, if so, to aid in the selection of dose and route of administration for future studies.

NCT ID: NCT01159561 Completed - Virus Clinical Trials

Western Equine Encephalitis Vaccine, Inactivated

WEE
Start date: February 2010
Phase: Phase 1
Study type: Interventional

This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.